Atrotas

Atrotas Uses, Dosage, Side Effects, Food Interaction and all others data.

Atrotas, a tertiary amine antimuscarinic, produces dilation and loss of accommodation by blocking the response of iris sphincter muscle and the accommodative ciliary muscle to cholinergic stimulation.

Atrotas is an anticholinergic drug that produces typical anticholinergic effects inducing mydriasis and cycloplegia. Other effects of structurally-related atropine that could also apply to homatropine include inhibition of secretions, tachycardia, relaxation of smooth muscle and central nervous effects including excitation .

Atrotas
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Atrotas
Availability	Prescription only
Generic	Homatropine
Homatropine Other Names	Homatropina, Omatropina
Related Drugs	Humira, dexamethasone ophthalmic, triamcinolone ophthalmic, azathioprine, atropine ophthalmic, cyclopentolate ophthalmic, Cyclogyl, Isopto Atropine, Mydriacyl, Tropicacyl
Type	Injection
Formula	C₁₆H₂₁NO₃
Weight	Average: 275.348 Monoisotopic: 275.15214354
Protein binding	No pharmacokinetic data available.
Groups	Approved
Therapeutic Class	Mydriatic and Cycloplegic agents
Manufacturer	Intas Pharmaceuticals Ltd Gx
Available Country	India
Last Updated:	September 19, 2023 at 7:00 am

Uses

Atrotas Hydrobromide sterile Eye Drops is used for use as a mydriatic and cycloplegic agent.

Atrotas is also used to associated treatment for these conditions: Strabismus

How Atrotas works

Atrotas is a competitive muscarinic receptor antagonist with a bulky aromatic group in place of the acetyl group of acetylcholine. It is expected to act in similar manner as atropine, producing similar parasympatholytic effects. By blocking muscarinic receptors and cholinergic signalling pathways, homatropine blocks the response of the iris sphincter muscle and cause the pupil to become unresponsive to light upon dilation or mydriasis. It also blocks the accommodative muscle of the ciliary body to cholinergic stimulation .

Dosage

Atrotas dosage

Mydriasis and cycloplegia for refraction:

Adult: Instill 1 or 2 drops of 2% solution, or 1 drop of 5% solution immediately before the procedure, repeat at 5-10 minute intervals if necessary.
Child: Instill 1 drop of 2% soln immediately before the procedure, repeat at 10-min intervals if necessary.

Uveitis:

Adult: Instill 1-2 drops of 2% or 5% solution bid-tid up to every 3-4 hr as needed.
Child: 3 mth- 2 yr: instill 1 drop of 0.5% soln once daily or on alternate days. >2 yr: instill 1 drop of 1% or 2% soln bid.

Side Effects

Hypersensitivity may occur as conjunctivitis.

Toxicity

Acute oral LD50 is 1200 mg/kg in rat, 1400 mg/kg in mouse, and 1000 mg/kg in guinea pig . Systemic toxicity may occur following topical overdose of structurally-related ophthalmic atropine, particularly in children. It is characterized by flushing and dryness of the skin, blurred vision, a rapid and irregular pulse, fever, convulsions and hallucinations, and the loss of neuromuscular coordination. Abdominal distension may be observed with infants. Severe intoxication is manifested by central nervous system depression, coma, circulatory and respiratory failure, and death . Symptomatic and supportive treatment should be initiated. In case of accidental use or overdose in infants and small children, the body surface should be kept moist .

Precaution

Should be used with caution in patients with prostatic enlargement and in patients suffering from paralytic ileus or pyloric stenosis.

Interaction

Effects may be increased by drugs with antimuscarinic effect such as; some antihistamines; phenothiazines; antipsychotics; TCAs; MAOIs or parasympathomimetics.

Food Interaction

No interactions found.